Turkey · Delayed Price · Currency is TRY IST:BIOEN Statistics
Total Valuation
IST:BIOEN has a market cap or net worth of TRY 5.67 billion. The enterprise value is 11.80 billion.
| Market Cap | 5.67B |
| Enterprise Value | 11.80B |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
IST:BIOEN has 500.00 million shares outstanding.
| Current Share Class | 500.00M |
| Shares Outstanding | 500.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 20.58% |
| Float | 197.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.15 |
| PB Ratio | 1.73 |
| P/TBV Ratio | 2.01 |
| P/FCF Ratio | 626.71 |
| P/OCF Ratio | 9.96 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 1,305.06 |
Financial Position
The company has a current ratio of 0.32, with a Debt / Equity ratio of 1.92.
| Current Ratio | 0.32 |
| Quick Ratio | 0.15 |
| Debt / Equity | 1.92 |
| Debt / EBITDA | 140.53 |
| Debt / FCF | 693.41 |
| Interest Coverage | -1.41 |
Financial Efficiency
Return on equity (ROE) is -17.98% and return on invested capital (ROIC) is -5.50%.
| Return on Equity (ROE) | -17.98% |
| Return on Assets (ROA) | -4.74% |
| Return on Invested Capital (ROIC) | -5.50% |
| Return on Capital Employed (ROCE) | -9.35% |
| Weighted Average Cost of Capital (WACC) | 6.61% |
| Revenue Per Employee | 3.16M |
| Profits Per Employee | -798,463 |
| Employee Count | 835 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 9.10 |
Taxes
In the past 12 months, IST:BIOEN has paid 312.61 million in taxes.
| Income Tax | 312.61M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.82% in the last 52 weeks. The beta is 0.30, so IST:BIOEN's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -56.82% |
| 50-Day Moving Average | 17.09 |
| 200-Day Moving Average | 17.77 |
| Relative Strength Index (RSI) | 28.06 |
| Average Volume (20 Days) | 11,323,865 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IST:BIOEN had revenue of TRY 2.64 billion and -666.72 million in losses. Loss per share was -1.33.
| Revenue | 2.64B |
| Gross Profit | -159.72M |
| Operating Income | -811.82M |
| Pretax Income | -354.11M |
| Net Income | -666.72M |
| EBITDA | -72.79M |
| EBIT | -811.82M |
| Loss Per Share | -1.33 |
Balance Sheet
The company has 136.05 million in cash and 6.27 billion in debt, with a net cash position of -6.13 billion or -12.26 per share.
| Cash & Cash Equivalents | 136.05M |
| Total Debt | 6.27B |
| Net Cash | -6.13B |
| Net Cash Per Share | -12.26 |
| Equity (Book Value) | 3.27B |
| Book Value Per Share | 6.54 |
| Working Capital | -1.97B |
Cash Flow
In the last 12 months, operating cash flow was 568.96 million and capital expenditures -559.92 million, giving a free cash flow of 9.04 million.
| Operating Cash Flow | 568.96M |
| Capital Expenditures | -559.92M |
| Depreciation & Amortization | n/a |
| Net Borrowing | 560.09M |
| Free Cash Flow | 9.04M |
| FCF Per Share | 0.02 |
Margins
Gross margin is -6.06%, with operating and profit margins of -30.80% and -25.30%.
| Gross Margin | -6.06% |
| Operating Margin | -30.80% |
| Pretax Margin | -13.44% |
| Profit Margin | -25.30% |
| EBITDA Margin | -2.76% |
| EBIT Margin | -30.80% |
| FCF Margin | 0.34% |
Dividends & Yields
IST:BIOEN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -11.77% |
| FCF Yield | 0.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 24, 2021. It was a forward split with a ratio of 3.3333333.
| Last Split Date | Nov 24, 2021 |
| Split Type | Forward |
| Split Ratio | 3.3333333 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |